GlassScriptPhysician profile
Michael A Selden
NPI 1114954203
$11,605.25
in general payments reported to CMS, 2019-2025
34 companies · $1,815 in 2025
The $1,815 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,513 · 2020: $1,517 · 2021: $487 · 2022: $853 · 2023: $1,720 · 2024: $1,701 · 2025: $1,815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,235.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,321.90 | 2019-2020 | |
| Abbvie INC. | $1,695.00 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,225.38 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,039.24 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $972.27 | 2019-2025 | Stelara, Tremfya, Simponi |
| Evoke Pharma, INC. | $385.96 | 2023-2025 | Gimoti |
| Ironwood Pharmaceuticals, INC | $309.93 | 2019-2024 | Linzess |
| Celgene Corporation | $290.65 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $289.44 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $233.41 | 2019-2025 | |
| Lilly USA, LLC | $210.31 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $191.40 | 2019-2023 | |
| Medtronic, INC. | $182.37 | 2023-2025 | Barrx, Beacon |
| Madrigal Pharmaceuticals | $169.40 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $161.87 | 2019-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $155.69 | 2022-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $115.66 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $99.47 | 2021-2022 | |
| Pfizer INC. | $85.83 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $83.24 | 2024 | Iqirvo |
| Braintree Laboratories, INC. | $58.20 | 2019-2024 | Sutab, Suflave |
| Qol Medical, LLC | $57.73 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $41.58 | 2021-2023 | |
| Echosens North America, INC. | $35.00 | 2019 | |
| Daiichi Sankyo INC. | $33.04 | 2021-2022 | |
| Shionogi INC | $32.08 | 2019 | |
| Mallinckrodt Hospital Products INC. | $23.34 | 2022 | |
| Amgen INC. | $22.00 | 2025 | Uplizna |
| Fujifilm Healthcare Americas Corporation | $19.75 | 2023 | Utaswako Afp-L3 |
| Amag Pharmaceuticals, INC. | $17.91 | 2019 | |
| Redhill Biopharma INC. | $17.08 | 2021 | |
| Alfasigma USA, INC. | $15.00 | 2020 | |
| Phathom Pharmaceuticals, INC. | $14.12 | 2025 | Voquezna |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Selden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.